Castle Biosciences (CSTL) Competitors $20.05 +0.20 (+1.01%) Closing price 04/30/2025 04:00 PM EasternExtended Trading$19.21 -0.84 (-4.19%) As of 07:35 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CSTL vs. VCYT, LFST, PGNY, ADUS, AGL, ARDT, NHC, PACS, TDOC, and VRDNShould you be buying Castle Biosciences stock or one of its competitors? The main competitors of Castle Biosciences include Veracyte (VCYT), LifeStance Health Group (LFST), Progyny (PGNY), Addus HomeCare (ADUS), agilon health (AGL), Ardent Health Partners (ARDT), National HealthCare (NHC), PACS Group (PACS), Teladoc Health (TDOC), and Viridian Therapeutics (VRDN). These companies are all part of the "healthcare" industry. Castle Biosciences vs. Veracyte LifeStance Health Group Progyny Addus HomeCare agilon health Ardent Health Partners National HealthCare PACS Group Teladoc Health Viridian Therapeutics Castle Biosciences (NASDAQ:CSTL) and Veracyte (NASDAQ:VCYT) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, community ranking, profitability, media sentiment, valuation, analyst recommendations, dividends and institutional ownership. Is CSTL or VCYT more profitable? Castle Biosciences has a net margin of 1.95% compared to Veracyte's net margin of -2.18%. Veracyte's return on equity of 3.02% beat Castle Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Castle Biosciences1.95% 1.47% 1.27% Veracyte -2.18%3.02%2.80% Do analysts recommend CSTL or VCYT? Castle Biosciences presently has a consensus price target of $38.75, suggesting a potential upside of 93.27%. Veracyte has a consensus price target of $42.60, suggesting a potential upside of 39.67%. Given Castle Biosciences' stronger consensus rating and higher probable upside, equities analysts clearly believe Castle Biosciences is more favorable than Veracyte.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Castle Biosciences 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00Veracyte 1 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.70 Which has better earnings & valuation, CSTL or VCYT? Castle Biosciences has higher earnings, but lower revenue than Veracyte. Castle Biosciences is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCastle Biosciences$332.07M1.74-$57.47M$0.6232.34Veracyte$445.76M5.33-$74.40M$0.30101.67 Does the media prefer CSTL or VCYT? In the previous week, Veracyte had 5 more articles in the media than Castle Biosciences. MarketBeat recorded 17 mentions for Veracyte and 12 mentions for Castle Biosciences. Castle Biosciences' average media sentiment score of 1.04 beat Veracyte's score of 0.58 indicating that Castle Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Castle Biosciences 6 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Veracyte 8 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Do insiders & institutionals believe in CSTL or VCYT? 92.6% of Castle Biosciences shares are held by institutional investors. 7.2% of Castle Biosciences shares are held by insiders. Comparatively, 1.3% of Veracyte shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Does the MarketBeat Community favor CSTL or VCYT? Veracyte received 358 more outperform votes than Castle Biosciences when rated by MarketBeat users. Likewise, 73.05% of users gave Veracyte an outperform vote while only 64.79% of users gave Castle Biosciences an outperform vote. CompanyUnderperformOutperformCastle BiosciencesOutperform Votes9264.79% Underperform Votes5035.21% VeracyteOutperform Votes45073.05% Underperform Votes16626.95% Which has more risk and volatility, CSTL or VCYT? Castle Biosciences has a beta of 1.11, suggesting that its stock price is 11% more volatile than the S&P 500. Comparatively, Veracyte has a beta of 2.03, suggesting that its stock price is 103% more volatile than the S&P 500. SummaryCastle Biosciences beats Veracyte on 9 of the 17 factors compared between the two stocks. Get Castle Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for CSTL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CSTL vs. The Competition Export to ExcelMetricCastle BiosciencesMedical laboratories IndustryMedical SectorNASDAQ ExchangeMarket Cap$578.34M$2.88B$5.56B$7.82BDividend YieldN/A31.29%5.11%4.22%P/E Ratio100.2613.2822.5118.48Price / Sales1.74188.21395.68103.60Price / CashN/A57.5638.1834.62Price / Book1.384.676.774.25Net Income-$57.47M-$22.21M$3.22B$248.23M7 Day Performance-4.20%-1.91%1.45%0.89%1 Month Performance1.37%3.24%3.97%3.53%1 Year Performance-8.95%11.50%16.14%5.08% Castle Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CSTLCastle Biosciences3.061 of 5 stars$20.05+1.0%$38.75+93.3%-4.9%$578.34M$332.07M100.26540Upcoming EarningsVCYTVeracyte3.9687 of 5 stars$30.60-1.7%$42.60+39.2%+55.9%$2.39B$445.76M-204.00790Upcoming EarningsShort Interest ↑Positive NewsLFSTLifeStance Health Group2.2202 of 5 stars$6.16-8.1%$8.58+39.3%+6.3%$2.37B$1.25B-23.696,640Upcoming EarningsPGNYProgyny1.1831 of 5 stars$21.37-0.3%$23.64+10.6%-28.8%$1.83B$1.17B36.85310Upcoming EarningsPositive NewsADUSAddus HomeCare4.6992 of 5 stars$97.28-3.9%$132.78+36.5%+8.7%$1.77B$1.15B22.2633,200Upcoming EarningsPositive NewsAGLagilon health1.6768 of 5 stars$4.14+3.5%$4.60+11.0%-22.5%$1.71B$6.06B-4.40650Upcoming EarningsAnalyst ForecastNews CoverageARDTArdent Health Partners2.7315 of 5 stars$11.61-7.2%$20.58+77.3%N/A$1.66B$5.97B0.0024,200Upcoming EarningsAnalyst RevisionPositive NewsNHCNational HealthCareN/A$90.31-2.0%N/AN/A$1.40B$1.30B11.3212,400Positive NewsPACSPACS Group3.1745 of 5 stars$8.58-7.3%$34.00+296.3%-61.5%$1.31B$3.56B0.0032,433Positive NewsTDOCTeladoc Health3.8001 of 5 stars$6.52-4.5%$10.82+66.0%-43.8%$1.14B$2.57B-1.135,100News CoverageVRDNViridian Therapeutics1.2599 of 5 stars$13.13flat$35.70+171.9%+2.2%$1.07B$302,000.00-3.0550Upcoming EarningsPositive News Related Companies and Tools Related Companies Veracyte Alternatives LifeStance Health Group Alternatives Progyny Alternatives Addus HomeCare Alternatives agilon health Alternatives Ardent Health Partners Alternatives National HealthCare Alternatives PACS Group Alternatives Teladoc Health Alternatives Viridian Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CSTL) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredChina’s next move could destroy U.S. techThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Castle Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Castle Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CSTL Stock Free CSTL Stock Alerts